Search the news
Search Results
Multiple Sclerosis (MS) Society Survey
Date: 6 September 2019
The objective of the ‘expert consortium for progression in Multiple Sclerosis (MS) clinical trials’, set up in 2017 is to design and deliver an efficient clinical trials platform to speed up the development of new treatments to slow (and ultimately stop) the progression of MS. The consortium was commissioned with building on the success of the UK MS Clinical trials network. With the help of the STOP-MS appeal the MS society plans to invest £100 million in MS research over the next 10 years.
The consortium was split into two broad strategy groups, “Treatment Selection” and “Trial design and delivery strategy”. The “Trial design and delivery strategy group” were tasked with:
• designing a scalable infrastructure platform that can deliver efficient MS trials
• proposing a trial design that can be run through the platform.
This “Trial design and delivery strategy group” was further broken down into 3 linked working groups:
1. “Infrastructure Working Group”. To design UK wide recruitment and trial delivery infrastructure
2. “Trial Design Working Group”. To generate a menu of design options for running efficient, scalable and flexible clinical trials
3. “Outcome Measures Working Group”. To develop list of primary and secondary outcome measures with focus on potential interim measures, horizon scanning, development and validation of emerging and future measures
One of the objectives of the Infrastructure Working Group is to develop a comprehensive plan for tackling barriers to recruitment, scalability, incentivisation, collaboration and consultation with NIHR Clinical Research Network (CRN) and Local Clinical Research Network (LCRN)); the “Recruitment and Engagement Strategy”
We are therefore now scoping out the opinion of both R&D departments and MS study team on our proposed Recruitment and Engagement Strategy. We do hope that you will be able to spend 10-15 minutes completed the enclosed survey and forwarding it to as many of your R&D colleagues who it may be relevant to.
Please could you respond to the survey by the 13th September 2019.
Complete the survey here